About Nizatidine API
Therapeutic CategoryGastro-Intestinal - GI
CAS Number
76963-41-2
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, Japan DMF, Korea DMF
Mechanism of Action
Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.
Related APIs
Esomeprazole Magnesium Trihydrate
Gastro-Intestinal - GI
Famotidine
Gastro-Intestinal - GI
Nizatidine
Gastro-Intestinal - GI
Pantoprazole Sodium
Gastro-Intestinal - GI
Vonoprazan Fumarate
Gastro-Intestinal - GI
Omeprazole Base (Crystalline)
Gastro-Intestinal - GI
Rabeprazole Sodium (Form Y)
Gastro-Intestinal - GI
Omeprazole Magnesium (Amorphous & Crystalline)
Gastro-Intestinal - GI
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
FAQs
Nizatidine belongs to a class of drugs known as H2 blockers.
-
Inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.
-
Duodenal & Gastric Ulcer, Erosive Esophagitis and Gastroesophageal Reflux Disease- 300 mg orally (150mg twice).
-
We offer Crystalline form (No specific Polymorphic Form is claimed).
-
XCEED Platform (or) write to us at [email protected].
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.